Skip to main content
Close
Home
Society of Hospital Medicine
Presented by Society of Hospital Medicine
Home
Twitter Facebook LinkedIn Instagram YouTube Hospital Medicine Exchange Email RSS Feed

Mitchel L. Zoler, PhD

Mitchel is a reporter for MDedge based in the Philadelphia area. He started with the company in 1992, when it was International Medical News Group (IMNG), and has since covered a range of medical specialties. Mitchel trained as a virologist at Roswell Park Memorial Institute in Buffalo, and then worked briefly as a researcher at Boston Children's Hospital before pivoting to journalism as a AAAS Mass Media Fellow in 1980. His first reporting job was with Science Digest magazine, and from the mid-1980s to early-1990s he was a reporter with Medical World News. @mitchelzoler

News

Medically suspect criterion can determine bariatric surgery coverage

Author:
Mitchel L. Zoler, PhD
Publish date: June 18, 2021

Some health insurers require certain patients seeking bariatric surgery to first-fail treatment with three...

  • Read More

News

Bariatric surgery cuts insulin needs in type 1 diabetes with severe obesity

Author:
Mitchel L. Zoler, PhD
Publish date: June 17, 2021

By substantially cutting weight and thereby boosting insulin sensitivity bariatric surgery helps patients with...

  • Read More

News

Bariatric surgery tied to fewer HFpEF hospitalizations

Author:
Mitchel L. Zoler, PhD
Publish date: June 15, 2021

Data from the U.S. National Inpatient Sample show a significant link between prior bariatric surgery and fewer...

  • Read More

News

‘Twincretin’ meets primary endpoints in five pivotal diabetes trials

Author:
Mitchel L. Zoler, PhD
Publish date: June 14, 2021

Lilly’s novel “twincretin” tirzepatide met its primary, A1c-lowering endpoint in five pivotal RCTs of patients...

  • Read More

News

Mavacamten boosts quality of life in patients with hypertrophic cardiomyopathy

Author:
Mitchel L. Zoler, PhD
Publish date: June 4, 2021

Oral mavacamten significantly improved quality of life in a prespecified secondary endpoint from the EXPLORER-HCM pivotal trial.

  • Read More

News

Dapagliflozin’s cost-effectiveness ‘intermediate’ for HFrEF

Author:
Mitchel L. Zoler, PhD
Publish date: June 3, 2021

Results from DAPA-HF and U.S. pricing show dapagliflozin costs about $84,000/quality-adjusted life year, which...

  • Read More

News

Prediabetes linked to higher CVD and CKD rates

Author:
Mitchel L. Zoler, PhD
Publish date: June 2, 2021

Data from more than 330,000 U.K. adults show that an A1c of 5.7%-6.4% links with higher rates of incident CKD and CVD events.

  • Read More

News

Rivaroxaban cut recurrent limb events in VOYAGER-PAD

Author:
Mitchel L. Zoler, PhD
Publish date: May 26, 2021

Analysis of both first and subsequent major adverse limb events in the VOYAGER-PAD trial documents ongoing...

  • Read More

News

Sotagliflozin’s HFpEF benefit confirmed by new analyses

Author:
Mitchel L. Zoler, PhD
Publish date: May 24, 2021

A meta-analysis of two pivotal trials for the SGLT1/2 inhibitor sotagliflozin prospectively documents a HFpEF...

  • Read More

News

FIDELIO-DKD: Finerenone cuts new-onset AFib in patients with type 2 diabetes and CKD

Author:
Mitchel L. Zoler, PhD
Publish date: May 18, 2021

A prespecified, exploratory analysis from the FIDELIO-DKD trial showed that the nonsteroidal MRA finerenone...

  • Read More

News

Ultrasound renal denervation drops BP in patients on triple therapy

Author:
Mitchel L. Zoler, PhD
Publish date: May 16, 2021

In a sham-controlled, randomized study, renal denervation with ultrasound cut systolic blood pressure by a...

  • Read More

News

PARADISE-MI: Sacubitril/valsartan can’t beat ramipril in patients with acute MI

Author:
Mitchel L. Zoler, PhD
Publish date: May 15, 2021

When treating patients with no history of heart failure within days of an acute myocardial infarction,...

  • Read More

News

FDA blazes path for ‘real-world’ evidence as proof of efficacy

Author:
Mitchel L. Zoler, PhD
Publish date: May 11, 2021

FDA leaders must finalize guidance this year on submitting real-world observational evidence for regulatory decisions on drug and device efficacy...

  • Read More

News

Finerenone scores second pivotal-trial success in patients with diabetic kidney disease

Author:
Mitchel L. Zoler, PhD
Publish date: May 10, 2021

Top-line results from FIGARO-DKD, the second pivotal trial for finerenone in patients with type 2 diabetes and...

  • Read More

News

Two treatments show early promise for hypothalamic obesity

Author:
Mitchel L. Zoler, PhD
Publish date: May 10, 2021

Both the ADHD drug dextroamphetamine, and a compound of a novel monoamine reuptake inhibitor and a beta-blocker...

  • Read More

Pages

  • « first
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • …
  • last »
An Official Publication of the Society of Hospital Medicine

Society of Hospital Medicine
Twitter Facebook LinkedIn Instagram YouTube Hospital Medicine Exchange Email RSS Feed

Copyright  © 2022 Frontline Medical Communications Inc., Newark, NJ, USA. All rights reserved. Unauthorized use prohibited. The information provided is for educational purposes only. Use of this Web site is subject to the medical disclaimer.

Menu Close